Prostate Magnetic Resonance Imaging in Patient With Previous Negative Biopsies
Prostate Magnetic Resonance Imaging in Patient With Previous Negative Biopsies
Prostate cancer has been the most common neoplastic disease in men in Finland over the last
 ten years. Prostate-specific antigen (PSA) plays an important role in screening of prostate
 cancer. However, PSA has a limited sensitivity and specificity for prostate cancer detection.
 Commonly, the diagnosis of prostate cancer is done by transrectal ultrasonography (TRUS)
 guided biopsy. Because of the low accuracy of TRUS a systematic biopsy is usually performed
 instead of targeted TRUS biopsy. While, as many as 47% of the ultra-sound guided biopsies may
 be false negative and biopsies carry a risk of increase in complications, there is an
 increasing interest in developing more accurate non-invasive imaging modalities.

 This study will enroll 150 men with previous negative biopsies and clinical suspicion of
 prostate cancer due to serum level of PSA higher than 2.5 ng/ml or abnormal digital rectal
 examination (DRE) or patients in active surveillance due to low risk prostate carcinoma.
 Anatomical magnetic resonance imaging (MRI) and diffusion weighted imaging (DWI) at 3 Tesla
 (T) magnetic field using surface coils will be used to non-invasively predict the presence or
 absence of prostate cancer. In addition to routine 12-core TRUS biopsies, targeted TRUS
 guided biopsy based on MRI findings will be performed.
Inclusion Criteria:

 -  Language spoken: Finnish or Swedish

 -  Clinical suspicion of prostate cancer and/or previous negative prostate biopsies and
 MRI target

 -  Previous diagnosis of prostate carcinoma and patient on active surveillance

 -  Mental status: Patients must be able to understand the meaning of the study

 -  Informed consent: The patient must sign the appropriate Ethics Committee (EC) approved
 informed consent documents in the presence of the designated staff

 Exclusion Criteria:

 -  Language spoken: Finnish or Swedish

 -  Clinical suspicion of prostate cancer and/or previous negative prostate biopsies and
 MRI target

 -  Previous diagnosis of prostate carcinoma and patient on active surveillance

 -  Mental status: Patients must be able to understand the meaning of the study

 -  Informed consent: The patient must sign the appropriate Ethics Committee (EC) approved
 informed consent documents in the presence of the designated staff